{"entity":{"id":"nct05481151","kind":"trial","name":"A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV","aka":[],"tldr":"A phase 3 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.","summary":"A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV is a phase 3 interventional study registered as NCT05481151 by PharmaEssentia, with 111 participants enrolled, started 2022-10-26 and due to reach its primary completion in 2025-06-30. Interventions recorded: P1101 (Ropeginterferon alfa-2b-njft) and Ropeginterferon alfa-2b-njft (P1101).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05481151","url":"https://clinicaltrials.gov/study/NCT05481151"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":["ropeginterferon-alfa-2b"],"companies":["pharmaessentia"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05481151","phase":"3","setting":"A Phase IIIb, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Polycythemia Vera (PV)","sponsor":"PharmaEssentia","enrolled":111,"outcomes":[]},"route":"/trials/nct05481151/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"drug":[{"id":"ropeginterferon-alfa-2b","kind":"drug","name":"Ropeginterferon alfa-2b","route":"/drugs/ropeginterferon-alfa-2b/"}],"company":[{"id":"pharmaessentia","kind":"company","name":"PharmaEssentia","route":"/companies/pharmaessentia/"}]}}